Novavax ($NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Shares of Novavax Inc. NVAX shed 2.41% to $7.68 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.35% to 18,285.16 ...

Novavax Inc (NVAX) outlines its strategic focus on partnerships and pipeline expansion while navigating revenue fluctuations ...

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...

Novavax (NVAX) stock jumped today following the release of the vaccine maker’s Q4 2024 earnings report. That follows its diluted earnings per ...

Novavax (NVAX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $1.44 per share a year ago. These figures are adjusted ...

Bullish option flow detected in Novavax (NVAX) with 9,851 calls trading, 2x expected, and implied vol increasing over 1 point to 83.26%. Jan-26 ...

Novavax Inc. closed 67.02% below its 52-week high of $23.86, which the company achieved on June 6th.